Dysregulation of lipid metabolism due to the M variant of PNPLA3 could favor the development of NAFLD-associated disease, such as cardiovascular disease (CVD). The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.